Brief: Supernus Pharmaceuticals posts Q2 revenue USD 135.5 million
08/08/2023 21:21
Aug 8 (Reuters) - Supernus Pharmaceuticals Q2 adjusted operating earnings USD 10 million. * Outlook FY revenue USD 580-620 million * Q2 revenue USD 135.5 million vs. IBES estimate USD 143.7 million
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing